Laboratorios Farmaceuticos Rovi, S.A. Stock Wiener Boerse
Stocks
ROVI
ES0157261019
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Wiener Boerse
2026-09-10
|
5-day change | 1st Jan Change | ||
| 57.40 EUR | -0.43% |
|
-2.79% | -9.32% |
| Jul. 23 | Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026 | |
| Jul. 23 | Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| Market Cap | 2.93B 3.4B 2.78B 2.52B 4.72B 325B 4.75B 32.98B 12.68B 165B 12.78B 12.5B 523B | P/E 2026 * |
20.5x | P/E 2027 * | 16.9x |
|---|---|---|---|---|---|
| Enterprise Value | 2.92B 3.39B 2.76B 2.5B 4.7B 323B 4.72B 32.8B 12.61B 165B 12.71B 12.44B 520B | EV / Sales 2026 * |
3.78x | EV / Sales 2027 * | 3.2x |
| Free-Float |
31.63% | Yield 2026 * |
1.71% | Yield 2027 * | 2.04% |
| Markets | Quality | ||
|---|---|---|---|
BME
| ROVI | Delayed | |
CBOE
| ROVIe | Real-time | |
|
OTC Markets
| LABFF | Delayed | |
|
Tradegate
| 41L | Real-time | |
|
Boerse Muenchen
| 41L | Real-time | |
|
Berne S.E.
| 41L | End-of-day quote | |
|
Deutsche Boerse AG
| 41L | Delayed | |
|
CBOE
| 0ILL | Real-time | |
|
Börse Stuttgart
| 41L | Delayed | |
|
Wiener Boerse
| ROVI | End-of-day quote | |
|
Borsa Italiana
| 1ROVI | End-of-day quote |
Last Transcript : Laboratorios Farmaceuticos Rovi, S.A.
| Jul. 23 | Spanish stocks - Factors to watch on July 23 | RE |
| Feb. 25 | Spanish stocks - Factors to watch on Feb 25 | RE |
| Nov. 06 | Spanish stocks - Factors to watch on Nov 6 | RE |
| 25-03-05 | Spanish stocks - Factors to watch on March 5 | RE |
| 1 day | -0.43% | ||
| 1 week | -2.79% | ||
| Current month | -5.44% | ||
| 1 month | -1.63% | ||
| 3 months | -1.96% | ||
| 6 months | -28.21% | ||
| Current year | -9.32% |
| 1 week | 57.3 |  | 58.7 |
| 1 month | 57.3 | | 61.8 |
| Current year | 53.15 | | 86.6 |
| 1 year | 53.15 | | 86.6 |
| 3 years | 45.82 | | 90.75 |
| 5 years | 35.64 | | 90.75 |
| 10 years | 35.64 | | 90.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2007-07-26 | |
| Director of Finance/CFO | - | 2000-12-31 | |
| Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 2021-07-16 | |
| Director/Board Member | - | 2007-07-26 | |
| Director/Board Member | - | 2007-07-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.43% | -2.79% | - | - | 3.4B | |
| -0.65% | -2.93% | +47.70% | +86.30% | 994B | |
| -0.29% | -3.51% | +49.15% | +61.95% | 640B | |
| +0.83% | +0.26% | +17.76% | +70.10% | 454B | |
| -0.38% | -3.59% | +30.13% | +34.14% | 337B | |
| -0.09% | -13.54% | +13.34% | +24.74% | 261B | |
| -0.43% | -2.48% | -0.73% | +10.64% | 246B | |
| -1.34% | -13.70% | +36.53% | +46.70% | 204B | |
| -3.44% | -7.51% | -20.63% | -58.97% | 190B | |
| -0.75% | -4.82% | +25.46% | +85.90% | 178B | |
| Average | -0.70% | -5.76% | +22.08% | +40.17% | 389.42B | |
| Weighted average by Cap. | -0.51% | -4.42% | +30.96% | +54.65% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 772M 896M 731M 662M 1.24B 85.57B 1.25B 8.68B 3.34B 43.53B 3.36B 3.29B 138B | 891M 1.03B 843M 765M 1.43B 98.77B 1.44B 10.02B 3.85B 50.25B 3.88B 3.8B 159B |
| Net income | 129M 149M 122M 110M 207M 14.25B 208M 1.45B 556M 7.25B 560M 548M 22.91B | 174M 202M 165M 149M 280M 19.28B 281M 1.96B 752M 9.81B 758M 741M 31B |
| Net Debt | -16.21M -18.82M -15.35M -13.92M -26.11M -1.8B -26.24M -182M -70.12M -915M -70.67M -69.12M -2.89B | -81.51M -94.6M -77.18M -69.95M -131M -9.04B -132M -917M -352M -4.6B -355M -347M -14.53B |
| Date | Price | Change |
|---|---|---|
| 26-09-11 | €57.70 | +0.52% |
| 26-09-10 | €57.40 | -0.43% |
| 26-09-09 | €57.65 | -1.54% |
| 26-09-08 | €58.55 | -0.68% |
| 26-09-07 | €58.95 | -0.17% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ROVI Stock
- ROVI Stock
Select your edition
All financial news and data tailored to specific country editions
